Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The current literature suggests that the mode of action of benralizumab is to deplete
eosinophils through a mechanism of antibody-dependent cell-mediated cytotoxicity. This direct
cellular cytotoxicity may not explain all of the benralizumab effects. The investigators
propose a set of studies to systematically examine the spectrum of effects of this drug on
the immune system.